Research Paper Volume 13, Issue 16 pp 20229—20245
Autophagic flux in cancer cells at the invasive front in the tumor-stroma border
- 1 Department of Immunology, Biochemistry and Molecular Biology, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease of the Ministry of Education, State Key Laboratory of Experimental Hematology, Tianjin Medical University, Tianjin, China
- 2 Department of Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Received: March 26, 2021 Accepted: August 2, 2021 Published: August 17, 2021
https://doi.org/10.18632/aging.203406How to Cite
Copyright: © 2021 Yan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Cancer cells at the invasive front directly interact with stromal tissue that provides a microenvironment with mechanical, nutrient, and oxygen supply characteristics distinct from those of intratumoral tissues. It has long been known that cancer cells at the invasive front and cancer cells inside the tumor body exhibit highly differentiated functions and behaviors. However, it is unknown whether cancer cells at different locations exhibit a variety of autophagic flux, an important catabolic process to maintain cellular homeostasis in response to environmental changes. Here, using transmission electron microscopy (TEM), we found that invading cancer cells at the invasive front, which show mesenchymal transcriptomic traits, exhibit higher autophagic flux than cancer cells inside the tumor body in human primary non-small cell lung cancer (NSCLC) tissues. This autophagic feature was further confirmed by a live cell autophagic flux monitoring system combined with a 3D organotypic invasion coculture system. Additionally, the increased autophagic flux endows cancer cells with invasive behavior and positively correlates with the advanced tumor stages and the reduced survival period of lung cancer patients. These findings expand the understanding of autophagic dynamics during cancer invasion.
Introduction
Metastasis is the leading cause of cancer-related deaths. Metastasis begins with local invasion, whereby cancer cells at the primary site invade the surrounding tissues and migrate towards the vascular systems. Solid tumors are highly heterogeneous and can often be anatomically classified into areas of the leading edge and tumor body [1–3]. Cancer cells at different locations are exposed to microenvironments with distinct mechanical, nutrient, oxygen supply, and pH characteristics [4], which affect their transcriptomics, metabolism, and signaling cascades and consequently resulting in dysregulated cellular behaviors [5–7]. Reports have shown that cancer cells at the leading edge are more invasive than cancer cells inside the tumor body [8–10].
Macroautophagy/autophagy (hereafter referred to as autophagy), a multistep lysosomal degradation pathway that supports nutrient recycling and metabolic adaptation, has been considered as a process that regulates cancer survival during stresses [11]. Although autophagy induction may inhibit tumors initiation [12], evidence in mouse models demonstrates that autophagy inhibition can limit the growth of established tumors and improve the response to cancer therapeutics [13, 14]. Targeting autophagy is becoming an attractive strategy for cancer treatment. However, an atlas of autophagy in human primary cancer tissue is still lacking. The autophagic properties of cancer cells at different locations in human primary cancer tissues remain undefined. As a biological process responding to the intracellular and environmental changes, autophagy should be highly different in every single cancer cells exposed to different environments and exhibiting different cellular behaviors [15, 16]. Understanding the autophagic state in cancer cells with different behaviors will facilitate the development of therapeutic strategies involving autophagy targeting.
In this report, we used toluidine blue-staining-directed transmission electron microscopy (TEM) to evaluate autophagic flux in cancer cells at different locations in human primary lung cancer tissues. We also developed an in vitro live cell autophagy monitoring system to assess the change of autophagy in cancer cells during the invading process. Our studies demonstrated that cancer cells at the leading edge exhibited higher autophagic flux than cancer cells inside the tumor body, providing an in vivo evidence for understanding dynamic and functional autophagy process in cancer.
Results
Cancer cells at the invasive front exhibit increased autophagic flux
We studied autophagic flux in cancer cells at different locations in human primary non-small cell lung cancers (NSCLCs) using ultrathin-section TEM. To precisely locate the invasive front in lung cancer tissues, we prescreened resin-embedded semi-thick sections of primary human lung cancer tissues, including two squamous lung cancers (LUSC) and two lung adenocarcinomas (LUAD), by toluidine blue staining, and the invasive front region was subjected to further TEM analysis (Figure 1A). Under TEM, we observed a large number of autophagy-related structures representing different stages of autophagy, such as phagophores, autophagosomes, amphisomes, and autolysosomes in the cells at the invasive front but not in cells inside the tumor body in both LUSC tissues and LUAD tissues (Figure 1A, 1B), suggesting that cancer cells at the invasive front may undergo very fast autophagic recycling.
Figure 1. The autophagic flux is increased at the tumor invasive front. (A) Toluidine blue staining of the LUSC and LUAD for TEM (left panel). The TEM images show the autophagic vacuoles (blue arrows) in tumor cells located at the invasive front and inside the tumor body of LUSC and LUAD (right panel). Dashed line, tumor-stroma border. Red arrows, leader cells and following cells in invasive front and cells inside the tumor body. The enlarged images show autophagic vacuoles, including phagophores (a and g), autophagosomes (b and h), amphisomes (c, e, f and i) and autolysosomes (d and j). Scale bars, 50 μm for toluidine blue staining and 1 μm for TEM. (B) The quantification of the autophagic vacuoles per cell located at the tumor invasive front and inside the tumor body (P = 0.0006 in LUSC, P = 0.0294 in LUAD). Error bars, means ± SEM for 10 cells in a representative experiment. (C) Representative immunohistochemistry (IHC) images of HSP60, TOMM20 and RSCA1 in LUSC specimens and tumor-adjacent tissues. Scale bars, 50 μm.
Interestingly, in these high autophagic cancer cells, less organelles including mitochondria, endoplasmic reticulum, or Golgi apparatus were observed (Figure 1A, 1B). Consistently, the heat shock protein 60 (HSP60), translocase of outer mitochondrial membrane 20 homologs (TOMM20) and the Golgi protein receptor binding cancer antigen expressed on SiSo cells (RCAS1) were less expressed at the invasive front, compared with the strong IHC signal of these proteins in the intratumoral cells (Figure 1C). Next, we evaluated the cellular functions by assessing the single-cell RNA-seq data of human primary lung cancers based on expression of mitochondria genes. We analyzed single-cell RNA-seq of six human primary LUADs including two stage I, three stage II and one stage III tumors in ArrayExpress under accessions E-MTAB-6149 and E-MTAB-6653 using the uniform manifold approximation and projection (UMAP) [17]. We removed the immune cells that expressed PTPRC/CD45, endothelial cells that expressed PECAM1/CD31, and fibroblast cells (Supplementary Figure 1) and regrouped the remaining cells using UMAP (Figure 2A, upper panel). Based on expression of mitochondria genes, cancer cells were divided into MTlo subgroup (lacking detectable expression of the mitochondria genes) and MThi subgroup (Figure 2A, lower panel and Supplementary Figure 2). Compared to MThi cancer cells, MTlo cancer cells exhibited upregulated mitophagy and glycolytic pathways, as expected, but downregulated cell-matrix adhesion pathway (Figure 2B). In addition, MTlo cancer cells expressed higher levels of SMTN1, TUBB, TUBA1A, and TUBA1B genes involved in microtubule turnover which contributes to cellular processes such as intracellular transport, cell division and migration, than MThi cancer cells did [18] (Figure 2C). Also, MTlo cells expressed high level of VIM but lack CDH1 (Figure 2D). These transcriptomic features suggest that the high autophagic MTlo cancer cells may reside in a mesenchymal state and exhibit reduced substrate-adherence while increased migration, and glycolysis. Consistently, cell surface expression of GLUT1 and phosphorylated AMPK (a protein that activate autophagy) were predominantly observed in cancer cells at the invasive front in immunostaining (Figure 2E). These collective results indicate that in human primary lung cancer tissues, invading cancer cells at the invasive front exhibit higher level of autophagic flux than cancer cells inside the tumor body.
Figure 2. High autophagic cancer cells exhibited low MT-gene signature. (A) After removing the immune, endothelial and fibroblast cells, and re-clustering the remaining cells, predicted normal epithelial cell types, including AT1 (alveolar type I) cells, AT2 (alveolar type II) cells and club cells, based on gene expression were labeled (upper panel), and visualization of MT-gene signature scores (MT-ATP8, MT-ATP6, MT-CO1, MT-CO2, MT-CO3, MY-CYB, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6) of malignant cells in 6 primary LUADs (lower panel). (B) GSEA analysis was performed to further screen the significant pathway between MTlo and MThi cancer cells. (C) Heatmap showing the expression level of the top 20 differentially expressed genes for MTlo and MThi clusters. (D) UMAP visualization of CDH1 and VIM of malignant cells in 6 primary LUADs. (E) IHC staining of phosphorylated AMPK (p-AMPK) and GLUT1 in tumor-adjacent tissue and LUSC tissue. Dashed line, tumor-stroma border. Scale bars, 50 μm.
Autophagic flux is elevated in invading cancer cells in vitro
Then, we sought to develop an in vitro system to monitor autophagic flux in the invading cancer cells. To do this, we combined a live cell autophagy monitoring system with a three-dimensional (3D) organotypic invasion coculture system. Knowing that paracrine interaction between human cancer-associated fibroblasts (CAFs) and malignant cells promotes invasion of malignant cells at the tumor-stroma border [1], we seeded lung adenocarcinoma cells A549 on the surface of a dense gel composed of collagen I and Matrigel, which closely mimics the tumor-associated microenvironment, with or without human CAFs embedded in the gels. As expected, A549 cells were able to invade the gel only when CAFs were embedded. In the absence of embedded CAFs, A549 cells grew only on the top of the gel and could not invade it (Figure 3A).
Figure 3. Autophagic degradation and recycling are elevated during the invading process. (A) H&E stained sections of 3D organotypic coculture gels. Scale bars, 50 μm. (B) The GFP/RFP ratio in single A549 cell colonies stable expressing the GFP-LC3-RFP-LC3ΔG cassette was determined under the indicated treatment. Scale bars, 200 μm. (C) Fluorescent images indicating GFP and RFP of A549 cells expressing GFP-LC3-RFP-LC3ΔG in cryosections of paraformaldehyde-fixed organotypic gels (upper panel) and GFP and RFP in a 3D volume rendering of live A549 cells expressing GFP-LC3-RFP-LC3ΔG (lower panel). White arrow, invasive front of A549 cells in the 3D organotypic coculture system. These fluorescent images of the gels in the 3D organotypic coculture system are representative of three independent experiments. Scale bars, 200 μm. The increments on the Z-axis indicate invasion distance (μm). (D) Representative images of H&E staining and GFP/RFP fluorescence in subcutaneous tumors formed by GFP-LC3-RFP-LC3ΔG-expressing A549 cells. Dashed line, tumor-stroma border. Scale bar, 200 μm for H&E staining and 50 μm for fluorescence images.
To monitor the autophagic flux in this model, we transduced the fluorescent probe GFP-LC3-RFP-LC3ΔG into A549 cells to assess the formation and degradation of LC3 puncta [19]. Upon autophagy activation, this probe is cleaved by endogenous ATG4 proteases into equimolar amounts of GFP-LC3 and RFP-LC3ΔG. GFP-LC3 is degraded by autophagic process, while RFP-LC3ΔG remains in the cytosol, serving as an internal control. Thus, the GFP/RFP signal ratio correlates inversely with autophagic activity. As expected, the autophagy inducer torin1 significantly decreased the GFP/RFP ratio, whereas the autophagy inhibitor bafilomycin A1 (Baf A1) increased this ratio (Figure 3B).
Next, we monitored intact autophagic flux in live cells in the 3D organotypic coculture invasion system under a laser scan confocal microscope. A549 cells did not invade and showed substantial cytosol yellow fluorescence in the organotypic gels without embedded CAFs (Figure 3C, upper panel). In comparison with A549 cells grown in the absence of CAFs, A549 cells formed a bulky invasive front in coculture with CAFs, with the GFP/RFP ratio gradually decreasing along the Z-axis from the tumor-stroma border in the direction of invasion (Figure 3C, upper panel). Additionally, as the scanning depth was increased, the invasion distance of the tumor cells increased, resulting in a decreased GFP/RFP ratio and suggesting enhanced autophagic flux in the invading cancer cells (Figure 3C, lower panel). Confocal imaging of cryosections of paraformaldehyde-fixed organotypic gels confirmed the reduced GFP/RFP ratio in the invading cancer cells (Figure 3C). Consistent with these observations, tumors formed from subcutaneous engraftments of GFP-LC3-RFP-LC3ΔG-expressing A549 cells exhibited a lower GFP/RFP ratio in the invasive front at the tumor-stroma border than inside the tumor body (Figure 3D). Taken together, the results of these in vitro and in vivo assays indicate that autophagy is increased in cancer cells at the invasive front, consistent with the results of our above TEM in human primary lung cancer tissues.
Elevated autophagic flux is required during the invasion process and potentiates cells invasiveness
Autophagy-related genes (ATGs) including ATG5, ATG6 (also known as BECN1), ATG7, and SQSTM1 are key components involved in specific steps during autophagosome biogenesis [20]. To further evaluate the impact of autophagy on the invasive ability of cancer cells, we depleted these ATGs by shRNA-mediated knockdown and tested the changes in invasion using the 3D organotypic coculture invasion system. Inhibition of ATG6, ATG5, ATG7, or Sequestosome 1 (SQSTM1)/p62 blocks the nucleation of the autophagosome, the expansion and completion of the autophagosome membrane, and the maturation and degradation of the autophagosome membrane, respectively [16]. Interestingly, depletion of these ATGs profoundly attenuated A549 cell invasion in the presence of CAFs in the 3D organotypic coculture invasion assay (Figure 4A, 4B). Therefore, impairment of autophagic initiation or autophagic degradation in lung cancer cells decreased invasion.
Figure 4. Deficient autophagy blocks cell invasion into organotypic gels. (A) The knockdown efficiency of shRNAs for autophagy-related proteins, including ATG5, ATG6, ATG7 and SQSTM1, was assessed by Western blotting. (B) Representative H&E-stained sections of ATG5-, ATG6-, ATG7- and SQSTM1-depleted A549 cells in the 3D organotypic coculture invasion system with or without human CAFs. The experiment was performed in triplicate. Scale bars, 50 μm. (C) The viability of A549 cells was evaluated by a CCK8 assay after 72 h of treatment with Tre, CQ, DMSO (vehicle control), or CoCl2 at the indicated concentration (upper panel). Error bars, means ± SD of a representative set of triplicate experiments. Immunoblots of HIF1α, LC3B, and SQSTM1 with the indicated treatment for 10 h, ACTB used as a loading control (lower panel). (D) The invasion capability of A549 cells was evaluated in the 3D organotypic coculture invasion system on gels with or without CAFs under treatment with DMSO, Tre (50 mM), CQ (50 μM), or CoCl2 (150 μM) for 10 days. The experiment was performed in triplicate. Scale bars, 50 μm. The number of invasive strands was quantified in 5 H&E-stained sections of each organotypic coculture gels. Error bars, means ± SD of a representative set of triplicate experiments.
Next, we modulated autophagic flux in the A549 cells using trehalose (Tre, an autophagy inducer) [21], CoCl2 (a hypoxia-dependent autophagy inducer) [22], or CQ (an autophagic degradation inhibitor) [23] to assess cell invasion in the same model, respectively. We treated the A549 cells with Tre, CQ, or CoCl2 at different concentrations and selected a dose at which cell viability was not affected but autophagic flux was changed, as evaluated by SQSTM1 accumulation and microtubule-associated protein 1 light chain 3 B (MAPLC3B/LC3B)-II/LC3B-I ratio (Figure 4C). Tre (50 mM) treatment and hypoxic condition (CoCl2, 150 μM) promoted more cells invading from the tumor-stroma border into the CAFs-containing gels, but CQ (50 μM) treatment completely inhibited this invasion (Figure 4D). Notably, even in the absence of CAFs, the elevated autophagic flux proficiently endowed A549 cells with invasive ability, whereas CQ treatment did not (Figure 4D). These results indicate that a high level of autophagic flux is required for cells invasion and is sufficient for the invasion of cancer cells in the absence of an interaction with stromal cells.
Increased SQSTM1-LC3B interaction at the tumor invasive front is correlated with poor prognosis for NSCLC patients
The physical interaction between SQSTM1 and LC3B is essential for autophagosome formation [24]. To accurately evaluate the location at which the SQSTM1/LC3B interactions occur, we used highly sensitive in situ proximity ligation assay (PLA) to assess the dynamic autophagic flux in cancer cells at different locations in the corresponding human lung cancer tissue sections, counterstained the tumor tissue sections with DIO, a dye to label membrane. Using this approach, we observed significantly more positive SQSTM1/LC3B interactive signals, most of which located in the cytosol, in cancer cells at the invasive front than in cancer cells inside the tumor body (Figure 5A).
Figure 5. Increased SQSTM1-LC3B interaction at the tumor invasive front is correlated with poor outcome in NSCLC patients. (A) Endogenous physical interactions between SQSTM1 and LC3B in LUSC sections were detected by in situ PLA (indicated by red fluorescent puncta) and visualized by laser scan confocal microscopy. Membrane structures were counterstained with a DIO probe (green). The enlarged regions show positive PLA signals of SQSTM1-LC3B protein complexes at the tumor invasive front (a-b). Scale bars, 50 μm. The scatter diagram of the PLA results shows the number of red fluorescent puncta per cell at the tumor invasive front and inside the tumor body (P < 0.0001). Error bars, means ± SEM for 30 cells in a representative experiment. (B) Representative images of in situ bright-field PLA of SQSTM1-LC3B protein complexes in NSCLC specimens and tumor-adjacent tissues, counterstained by Hematoxylin. Scale bars, 50 μm. (C) in situ PLA of SQSTM1-LC3B protein interaction was performed on tumor-adjacent lung tissues (n = 10), LUSC (n = 39), and LUAD (n = 99) specimens. The frequency of patient with undetectable (0), low (< 4.5), or high (4.6–9.0) PLA signal scores stratified by IHC-defined lung cancer subtype (ANOVA, P = 0.003) (left panel) or by NSCLC grade (ANOVA, P = 0.0045) (right panel). (D) Survival rates in 64 of the 148 NSCLC patients determined by Kaplan-Meier analysis were compared between patients with undetectable and low (PLA signals score ≤ 4.5, n = 48, blue line) and high (PLA signals score > 4.6, n = 16, red line) PLA signal scores for the SQSTM1-LC3B interaction. Three-year survival rates were 85% (undetectable and low PLA signal scores of SQSTM1-LC3B interaction) versus 33% (high PLA signal scores of SQSTM1-LC3B interaction; P = 0.028). (E and F), Representative IHC images of ATG7 and BECN1 in NSCLC specimens and tumor-adjacent tissues. Scale bars, 50 μm.
To investigate the correlation of autophagy at the invasive front with patient prognosis, we studied the interaction of SQSTM1 and LC3B in 148 NSCLC specimens, including 39 LUSC and 99 LUAD specimens, and in 10 tumor-adjacent lung tissues using bright-field PLA. No PLA signal of SQSTM1/LC3B interaction was detected in epithelial cells in tumor-adjacent lung tissues, indicating a relatively low autophagic flux (Figure 5B). The PLA signal of SQSTM1/LC3B interaction was found mainly in the cytoplasm of NSCLCs at the invasive front, consistent with the results of fluorescent PLA shown in Figure 5A, representing the high levels of autophagic flux at tumor invasive front (Figure 5B), consistent with our previous observations under TEM.
Quantification of PLA signals based on the intensity of PLA puncta and percentage of SQSTM1/LC3B complex-positive tumor cells revealed higher levels of SQSTM1/LC3B protein complexes in LUSCs than in LUADs (Figure 5C, left panel). In addition, a higher PLA signal score of the SQSTM1/LC3B interaction was associated with an advanced stage of NSCLC (Figure 5C, right panel). To assess the prognostic significance of SQSTM1/LC3B protein complexes, we examined their levels in resected NSCLC tissues from 64 subjects with known clinical outcomes. Patients with tumors showing undetectable and low PLA signal scores for SQSTM1/LC3B interaction (PLA signal score ≤ 4.5, n = 48) had longer disease-free survival time than patients whose tumors had high PLA signal score (PLA signal score > 4.5, n = 16), with three-year survival rates of 85% for those with low PLA signal score for the SQSTM1/LC3B interaction and 33% for those with high PLA signal scores (Figure 5D). These results indicate that the abundance of SQTM1/LC3B complexes is increased at the in invasive front of lung cancers and that this high abundance correlates with poor prognosis in human lung cancer. Consistently, we also noticed that the expression of ATG7 and BECN1 were predominantly located at the tumor edge rather than tumor nest by IHC in these tumor tissues (Figure 5E, 5F). Thus, the detection of the SQTM1/LC3B complex may have a value for predicting cancer cell invasiveness around the invasive front in clinical cancer samples. However, based on the dynamic autophagy changes in cancer cells, the use of autophagy-targeting therapies in cancer patients still require a much deeper understanding of autophagic processes that mediate cancer cell behaviors.
Discussion
Human lung cancers are widely known highly heterogeneous as revealed by transcriptomic, genomic, epigenomic, and proteomic profiles analysis [7, 25, 26]. In this study, we provide the in vivo evidence showing that cancer cells at the invasive front exhibit a higher level of autophagic flux than cancer cells inside the tumor body do. It is noteworthy that the high autophagic cancer cells at the invasive front contain very few other organelles such as mitochondria, Golgi, and ERs. This suggests that these high autophagic cancer cells do not rely on mitochondrial metabolism to generate ATP. Instead, they may adapt to glycolysis to meet ATP demand, which subsequently leads to lactate production, micro-environmental acidosis, and metastasis [27, 28]. This scenario is supported by our analysis of transcriptional profiling of those single lung cancer cells that lack expression of mitochondria encoded genes, showing the increased glycolytic and migratory profiles. Our findings are consistent with the observation that tumor cells exhibit rapid glucose uptake and lactate secretion, as well as suppression of mitochondrial metabolism [29].
It has been noticed that autophagy is dysregulated in many cancers and dysregulation of autophagy can be both tumor promotional and tumor suppressive, depending on the cellular context [16]. In established tumors, autolysosomal degradation promotes their ability to adapt to limiting nutrient supplies, therefore maintaining cellular aggressiveness [30, 31]. Although it is well established that autophagic inhibition represses cancer invasion, a full view of the diversity of autophagic states in human primary lung cancer tissues remain less certain. Our data suggest that a rapid autophagic recycling process might also be needed for mitochondria downregulation. The supporting data include 1) higher levels of cytoplasmic LC3/SQSTM1 complexes by in situ PLA, 2) the increased number of autophagic vesicles at the invasive front of human primary NSCLC tissue, and 3) the enhanced autophagic flux in the live invading cancer cells of the 3D organotypic cocultures. Indeed, the invading cancer cells locate at the tumor-stroma border and interact with a complex microenvironment containing extracellular matrix that provides active or passive mechanical cues [4], such as fibroblasts that secret various growth factors, cytokines, chemokines and proteinases [32], and leaky blood vessels that change the pH and oxygen supplement of the microenvironment [33]. We also examined hypoxic status by immunostaining for HIF1α in lung cancer tissue sections. Cancer cells at the invasive strand and cancer cells inside the tumor body, which exhibited different cytoplasmic/dot-like SQSTM1 staining, showed similar HIF1α staining intensity (data not shown). Thus, the elevated autophagic flux in invading cancer cells may not due to the limited nutrient or oxygen supplement.
In our 3D organotypic cocultures, cancer cells could not invade without CAFs embedded in the gel. The bottom layer of cancer cells directly interact with the gel which contains various soluble signals but does not show enhanced autophagic flux. With embedded CAFs in the gel, cancer cells started to invade. Invading cancer cells encounter CAFs and a physical force dictated by extracellular matrix besides those soluble signals in the gel. Given that both invading cancer cells and non-invading cancer cells interact with those soluble signals, it is possible that either one or both of physical force and CAFs caused enhanced autophagic flux. Mechanical cues elicit biochemical signals and regulate cell function and behavior through mechanotransduction [34]. For example, YAP/TAZ, downstream effectors of extracellular matrix dependent cellular mechanotransduction, can regulate autophagic flux in pancreatic and mammary cancer cells [35]. Nevertheless, tumor cell plasticity is required in transition states including epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET), which may vary based on the tumor type, the state of dissemination, and the context of tumor metastasis [36]. The invasive front cancer cells express the mesenchymal marker vimentin but lack the epithelial marker E-cadherin, and exhibit mesenchymal attributes [9]. Further studies and better models that cancer cells can imitate in vivo invasion are needed to illustrate whether rigidity of extracellular matrix is indispensable to the regulation of autophagic flux.
Since a higher level of autophagic flux is required and sufficient for cancer cells to invade into the surrounding microenvironment, inhibition of autophagic flux through knockdown of autophagy proteins or the use of conventional small inhibitory molecules suppressed the invasion of cancer cells. In contrast, inducing autophagy with an autophagic stimulator such as trehalose or CoCl2 endows cancer cells with invasive capability in a 3D organotypic coculture system. Furthermore, suppression of autophagy inhibits cellular invasion but not polarization, consistent with the previous reports [37–39]. However, suppression of autophagy can also promote cancer cell invasion [40–42], dictating the context-dependent autophagy on metastatic progression. The functional roles of tumor cells as well stromal cells within tumor microenvironment are extremely complex and are critical to diverse aspects of tumor biology [43].
In summary, our data showed that invading cancer cells require increased autophagic flux to migrate and invade at the invasive front. Targeting autophagy at the invasive front in the tumor-stroma border may serve as an adjuvant therapeutic strategy to improve treatment efficacy.
Materials and Methods
Human samples
Human lung cancer tissues were collected at Tianjin Medical University Cancer Hospital. The use of all human lung cancer tissues was approved by the Institutional Review Board of Tianjin Medical University. Informed consent was obtained from all patients, and samples were deidentified prior to analysis.
TEM
Samples from human primary lung cancer tissues were fixed in a fixative solution containing 6% glutaraldehyde followed by post-fixed with 2% osmium tetroxide (Sigma-Aldrich, 75632), thereafter were dehydrated in ascending ethanol solutions and absolute acetone, immersed in 50% Epon812 (Electron Microscopy Sciences, 14120) in acetone and embedded. The semi-thick sections were subjected to toluidine blue staining to identify the tumor invasive front and tumor body. The serial ultra-thin sections of invasive front and tumor body that identified by toluidine blue staining subsequently stained with uranyl acetate and lead citrate. Digital TEM images were acquired from thin sections using a HITACHI HT7700 transmission electron microscope (Hitachi High-Tech, Japan).
Cells, lentiviral transduction, and chemicals
A549 cells were purchased from ATCC and maintained in ATCC recommended media: RPMI1640 (Thermo Fisher Scientific) with 10% fetal bovine serum, 100 U of penicillin/mL, 100 μg of streptomycin/mL (Thermo Fisher Scientific). All experiments were performed within 1 month after thawing early-passage cells. A549 cells were tested negative for mycoplasma and were authenticated in April 2017. DNA purified from A549 cell lines were tested by the short tandem repeat analysis method using Promega PowerPlex 1.2 analysis system (Genewiz Inc.). Data were analyzed using GeneMapper4.0 software and then compared with the ATCC databases for reference matching. Human cancer-associated fibroblasts were isolated from primary lung tumors by physical fragmentation and 2 mg/ml collagenase (Sigma-Aldrich, C2139) digestion and maintained in DMEM supplemented with 10% FBS, 100 U of penicillin/mL, 100 μg of streptomycin/mL, 1% OriCellTM ITS (Cyagen) and 2 mM GlutaMAXTM-I (Thermo Fisher Scientific). For lentiviral transduction, Phoenix-293T cells were seeded in 100-mm plates and co-transfected with the target constructs and the packaging plasmids pMD2.VSVG, pMDLg/pRRE, and pRSV-REV. A549 cells were allowed to viral infect in 35-mm plates for 8 h and recover for 24 h prior to the further procedure. Single cell clones were developed for all the following assays. The autophagy inducers and inhibitors used in this study were purchased from Sigma-Aldrich: torin1 (475991), trehalose (Tre, T9531), Cobalt chloride hexahydrate (CoCl2, V900021), bafilomycin A1 (Baf A1, 196000), chloroquine (CQ, C6628). GFP-LC3-RFP-LC3ΔG probe was purchased from Addgene, 84572. The DNA sequences for shRNA knockdown assay are listed in Table 1. All primary antibodies for this study are listed in Table 2.
Table 1. shRNA sequences used in this study.
shRNA target sequence (5′–3′) | Efficiency (%) |
ATG5 (human, NM_00449) | |
#1 GCAACTCTGGATGGGATTG | 70 |
#2 AGTGAACATCTGAGCTACC | 80 |
ATG7 (human, NM_006395) | |
#1 GCCTGCTGAGGAGCTCTCCA | 80 |
#2 CCCAGCTATTGGAACACTGTA | 75 |
ATG6/NECN1 (human, NM_003766) | |
#1 ACAGGAGCTGGAAGATGTGGAA | 85 |
#2 AGCCAATAAGATGGGTCTGAAA | 80 |
SQSTM1/p62 (human, NM_003900) | |
#1 GGAGCACGGAGGGAAAAGATT | 70 |
#2 GTGACGAGGAATTGACAATTT | 84 |
Firefly luciferase (con) | |
CGTACGCGGAATACTTCGATT | Irrelevant control |
Table 2. Primary antibodies used in this study.
Primary Antibody | Dilution Ratio | Supplier | |
IHC/PLA | WB | ||
ATG5 | 1:100 | 1:5,000 | Abcam, ab109490 |
ACTB | 1:3,000 | Sigma-Aldrich, A-3853 | |
ATG7 | 1:100 | 1:1,0000 | Abcam, ab52472 |
BECN1 | 1:100 | BIOSS, bs-1353R | |
HSP60 | 1:100 | Santa Cruz Biotechnology, sc-376261 | |
RSCA1 | 1:100 | Abcam, ab16568 | |
TOMM20 | 1:100 | Abcam, ab186735 | |
LC3B | 1:100/1:100 | 1:2,000 | Sigma-Aldrich, L7543 |
SQSTM1/p62 | 1:400/1:100 | 1:1,000 | Abcam, ab56416 |
HIF1a | 1:400 | 1:3,000 | Abcam, ab51608 |
ATG6/BECN1 | 1:2,000 | Cell Signaling Technology, 3738 | |
p-AMPK | 1:100 | Cell Signaling Technology, 2535 | |
GLUT1 | 1:100 | Abcam, ab115730 |
3D organotypic coculture
The 3D organotypic coculture invasion assays were performed as follows: fibrillar rat-tail collagen I (Corning; 354249) and growth factor-reduced Matrigel (BD Biosciences; 356230) were mixed to generate a mixture gel containing collagen at 4 mg/ml and Matrigel at 2 mg/ml. Neutralized mixture gel 600 μL/well was then aliquoted onto a 0.4 μm polyester membrane (Corning Costar; 34818034). For assays involving the human cancer-associated fibroblasts (CAFs), 5 × 105 human CAFs were embedded in 1 ml mixture. The 3D organotypic coculture invasion gel with or without human CAFs was allowed to polymerize at 37 °C for about 1 h, after that 5 × 105 A549 cells were plated on the top of gel. The gel was fed from underneath with complete medium supplemented 1% insulin-transferrin-selenium (Thermo Fisher Scientific; 51500-056) and 2 mM GlutaMAXTM-I (Thermo Fisher Scientific). Medium was changed daily. Tumor cells invade into gels over a period of 8 to 10 days. Gel was fixed using 4% paraformaldehyde plus 1% glutaraldehyde in PBS and embedded in paraffin or optimal cutting temperature compound (SAKURA, T4583). 5 μm paraffin sections were subjected to Hematoxylin and Eosin (H&E) staining and 10 μm cryo-sections were visualized by confocal microscope.
in situ PLA
All the tumor tissues from the patients received standard surgical excision, after that, tumor tissues were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS, pH 7.4; Invitrogen, 10010023) for 24 h, embedded in paraffin, sectioned at 5 μm. in situ PLA was performed to visualize protein-protein interactions in lung cancer tissues. Briefly, paraffin-embedded tissues were deparaffinized and rehydrated using standard methods. After heat-mediated antigen retrieval in citrate buffer (10 mM citric acid, pH 6.0) at 100°C for 40 min, sections were permeabilized with PBS containing 0.5% Triton X-100 (Sigma-Aldrich, SLCD3237) for 30 min, subsequently blocked in Blocking Solution (Sigma-Aldrich, DUO92004) at 37°C for 1 h and incubated with primary antibodies overnight at 4°C. On the following day, sections were washed twice with washing buffer (Sigma-Aldrich, DUO82049), and incubated with PLA probes in a ratio of 1:10 in antibody diluent for 1 h at 37°C. The sections were then incubated with ligation solution at 37°C for 30 min and subsequently with amplification solution at 37°C for 120 min. For fluorescent PLA, the tumor tissue sections were counterstained with 3, 3’-dioctadecyloxacarbocyanine perchlorate (DIO, Beyotime, C1038), a dye to label membrane or mounting medium (Origene, ZLI-9557) together with DAPI for 10 min. Cell images were captured with a confocal microscope (Carl Zeiss, Axio Imager A2, Germany). For bright-field PLA, sections were incubated with Detection Solution (Sigma-Aldrich, DUO92012B) at room temperature for 60 min and then developed with Substrate Solution (Sigma-Aldrich, DUO92012B) for 5–10 min. Nuclear was stained with Nuclear Stain (Sigma-Aldrich, DUO92012B) for 5 min.
For evaluation of PLA signal score of SQSTM1-LC3B complex in tumor tissue array, we defined the PLA puncta expression patterns into an intensity score from 0-3 for quantitative evaluation as follows: score 0, no puncta or barely visible puncta in <5% of the cells; score 1, detectable puncta in 5–25% of cells; score 2, readily detectable puncta in 25–75% of cells; score 3, puncta in >75% of cells. The number of cytoplasmic PLA puncta was assessed as absent (score 0), weak (score 1), moderate (score 2) or strong (score 3). Cytoplasmic PLA signal for SQSTM1-LC3B complex was classified as low and undetectable signal for a score of 0–4.5 and high signal for a score of 4.6–9.0.
Single-cell RNA-seq data accessibility and processing
We accessed processed data of single-cell RNA-seq from ArrayExpress database (Accessions # E-MTAB-6149 and E-MTAB-6653) for our analysis [17]. To visualize the processed data from Cell Ranger analysis, we utilized Seurat suite version 3.1 to perform cell clustering. First, filtered gene-barcode matrix of the sample identified by Cell Ranger Count was inputted into Seurat. Low quality cells/dying cells were removed, and we retained the cells with properly molecular read count and gene number (nCount_RNA < 50000, nFeature_RNA < 6000, and nFeature_RNA >200) and with low mitochondrial transcript proportion (percent.mt < 25). Then we normalized and scaled the data, and then performed linear dimensional reduction by PCA (Principal components analysis) on the scaled data. Next, we clustered and visualized the cell distribution by UMAP (Uniform Manifold Approximation and Projection). By checking the know cell type markers, we well defined normal mesenchymal cells, epithelial cells and cancer cells. Then the cancer cell extraction and other further analysis were also performed by Seurat package and gene expression was visualized by UMAP.
Single-cell RNA-seq differentially expressed (DE) gene identification
Tumor cells with low expression of 13 mitochondrial genome code genes were subset from the other tumor cells using “Subset” function and cells expressing both low and high mitochondrial genes were used for further analysis as two groups. DE genes were identified by “Find All Markers” command and top 20 genes of each group were visualized by heatmap on 100 randomly selected cells from each group by “downsample = 100”.
Xenograft assay
2 × 107 cells (1:1 of GFP-LC3-RFP-LC3ΔG-expressing A549 cells and CAFs) were suspended in 100 μL medium containing 50% Matrigel and were subcutaneously injected into 8-week-old female nude mice. 8 weeks after the inoculation, the mice were sacrificed and the tumors were dissected for further analysis. All animal procedures were approved by Animal Care and Use Committee at Tianjin Medical University and conform to the legal mandates and national guidelines for the care and maintenance of laboratory animals.
Immunohistochemistry (IHC)
For IHC staining, antibodies were processed following the standard protocol. Briefly, deparaffinized and rehydrated using standard methods. After heat-mediated antigen retrieval in citrate buffer (10 mM citric acid, pH 6.0) at 100°C for 40 min, sections were blocked with a solution of 10% normal goat serum (NGS) in PBS at room temperature for 30 min. For primary antibody, an overnight incubation at 4°C was followed by 2 h incubation at room temperature with secondary antibodies (Thermo Fisher Scientific). Sections were then stained with the DAB (diaminobenzidine) substrate kit (ORIGENE, ZLI-9017), washed with deionized water and counterstained with Hematoxylin.
Confocal microscopy
To obtain GFP and RFP fluorescence signals in the 3D organotypic coculture invasion system, gels was placed onto the glasses without fixing at the endpoint of the experiment. The Zst images were captured using a laser scanning confocal microscope immediately (Carl Zeiss, Axio Imager A2, Germany). In brief, serial scanning was performed at the XY level by moving the scanning depth under identical imaging conditions, including the same high voltage, offset and gain settings, same frame size, same pixel size, and same z-stack interval (5 μm) to acquire z-series images. During the process, RFP signals were uniformly strong irrespective of depth from the surface and accurately matched GFP signals. For 3D reconstructions, 14 (– CAFs) and 30 (+ CAFs) slices of 5 μm each from the whole 3D organotypic coculture invasion gels were fluorescently imaged, and the 3D volume render were performed by the extended depth of focus after stacking images along the Z-axis sequentially. Inserts in the z-axis represented the sum of z slices of 3D organotypic coculture invasion gels and illustrated the depth-distribution of fluorescence.
Western blot
Protein lysates of cells were prepared using RIPA buffer (Thermo Fisher Scientific, 89900) and protein concentration was quantified using the BCA protein assay kit (Thermo Fisher Scientific, 23235) after sonication. Primary antibodies diluted in blocking buffer were incubated overnight at 4°C followed by a 2 h incubation of secondary goat-anti-rabbit IgG and goat-anti-mouse IgG antibodies (Thermo Fisher Scientific, 1:10,000) at room temperature. Membranes were visualized using the Amersham Imager 600 system (GE Healthcare, USA).
CCK8 assay
Cell viability was examined using the Transdetect Cell Counting Kit (Transgen, Beijing, China) according to the manufacturer’s instructions. Briefly, A549 cells were grown in a 96-well plate for 24 h, followed by the treatment with DMSO, Tre, CQ or CoCl2 for the indicated time, respectively. To measure the cell viability, 10 μL of CCK-8 was added to each well for 2 h. Absorbance was measured at a wavelength of 450 nm.
Statistical analysis
Our experimental data were summarized as the mean ± standard error or mean ± deviation and statistically analyzed using a t-test and ANOVA. Graphpad 7 was used for statistical analysis. High vs. low and undetectable PLA signal score of SQSTM1-LC3B protein interaction was statistically analyzed using the Kaplan-Meier curves and the log-rank test for the disease-free survival of lung cancer patients. A P-value of less than 0.05 was considered statistically significant.
Supplementary Materials
Supplementary Figures
Author Contributions
Yan and X. Zhang performed the experiments and analyzed the data. R. Tan performed the immunostaining of mitochondrial and Golgi proteins. M. Li prepared tissue sections. Z. Xiao, H. Wang and Z. Zhang collected the human tumor samples. Z. Ma and Z. Liu conceived the experiments and contributed to the interpretation and to writing the manuscript. All authors revised and approved the manuscript.
Conflicts of Interest
The authors declare no conflicts of interest related to this study.
Funding
This work was supported by the Ministry of Science and Technology of China (grant 2018YFC1313002 to Z.L.), the National Natural Science Foundation of China (grants 81825017, 81773034 to Z.L., 81872350 to Z.M., 81772488 to Z.Z.), the Tianjin Municipal Science and Technology Commission (grants 20JCZDJC00110 to Z.L., 18JCZDJC99100 to Z.M.), Tianjin Medical University Postgraduate Innovation Fund of “13th Five-Year comprehensive investment” (YJSCX201805).
References
- 1. Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS, Deschler DG, Varvares MA, Mylvaganam R, et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell. 2017; 171:1611–24.e24. https://doi.org/10.1016/j.cell.2017.10.044 [PubMed]
- 2. Schürch CM, Bhate SS, Barlow GL, Phillips DJ, Noti L, Zlobec I, Chu P, Black S, Demeter J, McIlwain DR, Kinoshita S, Samusik N, Goltsev Y, Nolan GP. Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. Cell. 2020; 182:1341–59.e19. https://doi.org/10.1016/j.cell.2020.07.005 [PubMed]
- 3. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007; 9:1392–400. https://doi.org/10.1038/ncb1658 [PubMed]
- 4. Kai F, Drain AP, Weaver VM. The Extracellular Matrix Modulates the Metastatic Journey. Dev Cell. 2019; 49:332–46. https://doi.org/10.1016/j.devcel.2019.03.026 [PubMed]
- 5. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015; 27:15–26. https://doi.org/10.1016/j.ccell.2014.12.001 [PubMed]
- 6. Robertson-Tessi M, Gillies RJ, Gatenby RA, Anderson AR. Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. Cancer Res. 2015; 75:1567–79. https://doi.org/10.1158/0008-5472.CAN-14-1428 [PubMed]
- 7. Teixeira VH, Pipinikas CP, Pennycuick A, Lee-Six H, Chandrasekharan D, Beane J, Morris TJ, Karpathakis A, Feber A, Breeze CE, Ntolios P, Hynds RE, Falzon M, et al. Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nat Med. 2019; 25:517–25. https://doi.org/10.1038/s41591-018-0323-0 [PubMed]
- 8. Lee CK, Jeong SH, Jang C, Bae H, Kim YH, Park I, Kim SK, Koh GY. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science. 2019; 363:644–49. https://doi.org/10.1126/science.aav0173 [PubMed]
- 9. Du W, Xu X, Niu Q, Zhang X, Wei Y, Wang Z, Zhang W, Yan J, Ru Y, Fu Z, Li X, Jiang Y, Ma Z, et al. Spi-B-Mediated Silencing of Claudin-2 Promotes Early Dissemination of Lung Cancer Cells from Primary Tumors. Cancer Res. 2017; 77:4809–22. https://doi.org/10.1158/0008-5472.CAN-17-0020 [PubMed]
- 10. Ji AL, Rubin AJ, Thrane K, Jiang S, Reynolds DL, Meyers RM, Guo MG, George BM, Mollbrink A, Bergenstråhle J, Larsson L, Bai Y, Zhu B, et al. Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma. Cell. 2020; 182:497–514.e22. https://doi.org/10.1016/j.cell.2020.05.039 [PubMed]
- 11. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B, et al. Autophagy in malignant transformation and cancer progression. EMBO J. 2015; 34:856–80. https://doi.org/10.15252/embj.201490784 [PubMed]
- 12. Liu Z, Chen P, Gao H, Gu Y, Yang J, Peng H, Xu X, Wang H, Yang M, Liu X, Fan L, Chen S, Zhou J, et al. Ubiquitylation of autophagy receptor Optineurin by HACE1 activates selective autophagy for tumor suppression. Cancer Cell. 2014; 26:106–20. https://doi.org/10.1016/j.ccr.2014.05.015 [PubMed]
- 13. Wen X, Klionsky DJ. At a glance: A history of autophagy and cancer. Semin Cancer Biol. 2020; 66:3–11. https://doi.org/10.1016/j.semcancer.2019.11.005 [PubMed]
- 14. Yang Y, Klionsky DJ. Autophagy and disease: unanswered questions. Cell Death Differ. 2020; 27:858–71. https://doi.org/10.1038/s41418-019-0480-9 [PubMed]
- 15. Mowers EE, Sharifi MN, Macleod KF. Autophagy in cancer metastasis. Oncogene. 2017; 36:1619–30. https://doi.org/10.1038/onc.2016.333 [PubMed]
- 16. Towers CG, Wodetzki D, Thorburn A. Autophagy and cancer: Modulation of cell death pathways and cancer cell adaptations. J Cell Biol. 2020; 219:e201909033. https://doi.org/10.1083/jcb.201909033 [PubMed]
- 17. Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, Bassez A, Decaluwé H, Pircher A, Van den Eynde K, Weynand B, Verbeken E, De Leyn P, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018; 24:1277–89. https://doi.org/10.1038/s41591-018-0096-5 [PubMed]
- 18. Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, Muley T, Meister M, Hoffmann H, Penzel R, Gdynia G, Ehemann V, Schnabel PA, et al. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res. 2009; 69:2234–43. https://doi.org/10.1158/0008-5472.CAN-08-3338 [PubMed]
- 19. Kaizuka T, Morishita H, Hama Y, Tsukamoto S, Matsui T, Toyota Y, Kodama A, Ishihara T, Mizushima T, Mizushima N. An Autophagic Flux Probe that Releases an Internal Control. Mol Cell. 2016; 64:835–49. https://doi.org/10.1016/j.molcel.2016.09.037 [PubMed]
- 20. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12:1–222. https://doi.org/10.1080/15548627.2015.1100356 [PubMed]
- 21. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 2007; 282:5641–52. https://doi.org/10.1074/jbc.M609532200 [PubMed]
- 22. Wu H, Huang S, Chen Z, Liu W, Zhou X, Zhang D. Hypoxia-induced autophagy contributes to the invasion of salivary adenoid cystic carcinoma through the HIF-1α/BNIP3 signaling pathway. Mol Med Rep. 2015; 12:6467–74. https://doi.org/10.3892/mmr.2015.4255 [PubMed]
- 23. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 2007; 117:326–36. https://doi.org/10.1172/JCI28833 [PubMed]
- 24. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Øvervatn A, Bjørkøy G, Johansen T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007; 282:24131–45. https://doi.org/10.1074/jbc.M702824200 [PubMed]
- 25. Hoang LT, Domingo-Sabugo C, Starren ES, Willis-Owen SAG, Morris-Rosendahl DJ, Nicholson AG, Cookson WOCM, Moffatt MF. Metabolomic, transcriptomic and genetic integrative analysis reveals important roles of adenosine diphosphate in haemostasis and platelet activation in non-small-cell lung cancer. Mol Oncol. 2019; 13:2406–21. https://doi.org/10.1002/1878-0261.12568 [PubMed]
- 26. Zhang X, Nguyen KD, Rudnick PA, Roper N, Kawaler E, Maity TK, Awasthi S, Gao S, Biswas R, Venugopalan A, Cultraro CM, Fenyö D, Guha U. Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V. Mol Cell Proteomics. 2019; 18:622–41. https://doi.org/10.1074/mcp.RA118.001266 [PubMed]
- 27. Poillet-Perez L, White E. Role of tumor and host autophagy in cancer metabolism. Genes Dev. 2019; 33:610–19. https://doi.org/10.1101/gad.325514.119 [PubMed]
- 28. Singh SS, Vats S, Chia AY, Tan TZ, Deng S, Ong MS, Arfuso F, Yap CT, Goh BC, Sethi G, Huang RY, Shen HM, Manjithaya R, Kumar AP. Dual role of autophagy in hallmarks of cancer. Oncogene. 2018; 37:1142–58. https://doi.org/10.1038/s41388-017-0046-6 [PubMed]
- 29. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011; 11:325–37. https://doi.org/10.1038/nrc3038 [PubMed]
- 30. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X, Snyder E, Santanam U, Dipaola RS, et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 2013; 27:1447–61. https://doi.org/10.1101/gad.219642.113 [PubMed]
- 31. Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R, Sykacek P, Frank L, Schramek D, Komnenovic V, Sigl V, Aumayr K, Schmauss G, et al. A dual role for autophagy in a murine model of lung cancer. Nat Commun. 2014; 5:3056. https://doi.org/10.1038/ncomms4056 [PubMed]
- 32. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; 6:392–401. https://doi.org/10.1038/nrc1877 [PubMed]
- 33. Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017; 20:409–26. https://doi.org/10.1007/s10456-017-9562-9 [PubMed]
- 34. Park JS, Burckhardt CJ, Lazcano R, Solis LM, Isogai T, Li L, Chen CS, Gao B, Minna JD, Bachoo R, DeBerardinis RJ, Danuser G. Mechanical regulation of glycolysis via cytoskeleton architecture. Nature. 2020; 578:621–26. https://doi.org/10.1038/s41586-020-1998-1 [PubMed]
- 35. Totaro A, Zhuang Q, Panciera T, Battilana G, Azzolin L, Brumana G, Gandin A, Brusatin G, Cordenonsi M, Piccolo S. Cell phenotypic plasticity requires autophagic flux driven by YAP/TAZ mechanotransduction. Proc Natl Acad Sci U S A. 2019; 116:17848–57. https://doi.org/10.1073/pnas.1908228116 [PubMed]
- 36. Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK. EMT, MET, Plasticity, and Tumor Metastasis. Trends Cell Biol. 2020; 30:764–76. https://doi.org/10.1016/j.tcb.2020.07.003 [PubMed]
- 37. Hamurcu Z, Delibaşı N, Geçene S, Şener EF, Dönmez-Altuntaş H, Özkul Y, Canatan H, Ozpolat B. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/Src signaling in triple negative breast cancer cells. J Cancer Res Clin Oncol. 2018; 144:415–30. https://doi.org/10.1007/s00432-017-2557-5 [PubMed]
- 38. Tong H, Yin H, Hossain MA, Wang Y, Wu F, Dong X, Gao S, Zhan K, He W. Starvation-induced autophagy promotes the invasion and migration of human bladder cancer cells via TGF-β1/Smad3-mediated epithelial-mesenchymal transition activation. J Cell Biochem. 2019; 120:5118–27. https://doi.org/10.1002/jcb.27788 [PubMed]
- 39. Zhang L, Liu X, Song L, Zhai H, Chang C. MAP7 promotes migration and invasion and progression of human cervical cancer through modulating the autophagy. Cancer Cell Int. 2020; 20:17. https://doi.org/10.1186/s12935-020-1095-4 [PubMed]
- 40. Catalano M, D'Alessandro G, Lepore F, Corazzari M, Caldarola S, Valacca C, Faienza F, Esposito V, Limatola C, Cecconi F, Di Bartolomeo S. Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells. Mol Oncol. 2015; 9:1612–25. https://doi.org/10.1016/j.molonc.2015.04.016 [PubMed]
- 41. Qiang L, Zhao B, Ming M, Wang N, He TC, Hwang S, Thorburn A, He YY. Regulation of cell proliferation and migration by p62 through stabilization of Twist1. Proc Natl Acad Sci U S A. 2014; 111:9241–46. https://doi.org/10.1073/pnas.1322913111 [PubMed]
- 42. Wang Y, Xiong H, Liu D, Hill C, Ertay A, Li J, Zou Y, Miller P, White E, Downward J, Goldin RD, Yuan X, Lu X. Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells. Autophagy. 2019; 15:886–99. https://doi.org/10.1080/15548627.2019.1569912 [PubMed]
- 43. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging Biological Principles of Metastasis. Cell. 2017; 168:670–91. https://doi.org/10.1016/j.cell.2016.11.037 [PubMed]